Bristol Myers Squibb stock trades at EUR 54.23 as revenue rose 5.7 percent

Published on 10/16/2026 at 09:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 12.97 billion, up 5.7 percent year over year. Bristol Myers Squibb stock costs EUR 54.23 on October 16, 2026.

Revenue and analyst pressure

Second-quarter revenue reached USD 12.97 billion on July 30, 2026.
Wells Fargo cut its target from USD 65.00 to USD 60.00 on October 13, 2026.
Bristol Myers Squibb stock was trading at EUR 54.23 at 8:59 a.m. CEST at Lang & Schwarz on October 16, 2026.
Third-quarter results are scheduled for October 29, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) was quoted at EUR 54.23 at Lang & Schwarz on October 16, 2026 at 8:59 a.m. CEST, while second-quarter 2026 revenue rose 5.7 percent year over year to USD 12.97 billion, according to Ticker Scout. The revenue figure gives the stock a stronger operating backdrop, but analysts have recently lowered some targets.

Recent figures and targets

Bristol Myers Squibb reported USD 3.32 billion of net earnings attributable to the company in the quarter ended June 30, 2026, compared with USD 1.31 billion a year earlier. Diluted earnings per share reached USD 1.62 versus USD 0.64, although Ticker Scout attributed much of the earnings increase to charges that did not repeat.

On October 13, 2026, Investing.com reported that Wells Fargo cut its target from USD 65.00 to USD 60.00 while maintaining an Equal Weight rating. The firm cited upcoming loss of exclusivity for Eliquis in parts of Europe and questions about the efficacy and safety profile of admilparant.

Three dated developments

On July 30, 2026, second-quarter revenue reached USD 12.97 billion and adjusted earnings per share reached USD 2.04, according to MarketBeat. On October 5, 2026, Leerink Partners cut its target to USD 59.00 from an earlier USD 73.00, as reported by MarketBeat. On October 13, 2026, Wells Fargo reduced its target to USD 60.00 from USD 65.00.

What dates matter next?

Third-quarter results are due on October 29, 2026, according to the recent company calendar information carried by Ticker Scout. The next filing is expected to cover the quarter ended September 30, 2026.

Premarket price and valuation

MarketBeat listed a USD 115.83 billion market value, a USD 42.52 52-week low and a USD 68.64 52-week high on October 13, 2026. The EUR 54.23 Lang & Schwarz quotation gives German investors a dated premarket reference, while the latest analyst target changes keep attention on Eliquis exposure and pipeline execution.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.